SCOTTSDALE, AZ and URMOND, THE NETHERLANDS--(Marketwire - Mar 20, 2013) - RiceBran Technologies (OTCQB: RIBT), a global leader in the production and marketing of value added products derived from rice bran, and Royal DSM ("DSM") announced today that the companies completed the Joint Research and Development Agreement ("JRDA") initiated in November 2011.
Under the terms of the agreement, DSM and RiceBran Technologies have developed new technology which can be used to produce first generation protein products from rice bran.
Pursuant to the completion of the JRDA, each party holds the right to further develop and commercialize the resulting first generation technology for its own benefit.
About RiceBran Technologies
RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. RiceBran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in the Company's filings with the SEC and by visiting our website at www.ricebrantech.com.
DSM - Bright Science. Brighter Living.™
Royal DSM N.V., a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about EUR 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
This release contains forward-looking statements, including statements about the commercialization of protein derived from rice bran and the demand for the technology jointly developed by DSM and RiceBran Technologies. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies' filings with the Securities and Exchange Commission, including the Company's most recent periodic reports.